Paper

Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.

Published Sep 1, 2018 · S. Cherukupalli, B. Chandrasekaran, V. Kryštof

Bioorganic chemistry

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Study Snapshot

Novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines show promising anticancer activity, with compounds showing significant CDK2 inhibitory activity and anti-proliferative effects against K-562 and MCF-7 cancer cell lines.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.

References

Citations